The Federal Trade Commission is suing the three largest prescription drug benefit managers (PBMs) for allegedly driving up ...

The Federal Trade Commission's administrative complaint follows an interim report from the agency regarding PBM practices.

Opens in a new tab or window Physicians frequently cite prior authorization requirements ... However, some groups did express concerns. A 2022 report from America's Health Insurance Plans (AHIP ...

Cigna division Express Scripts announced Friday that it's joining ... Biosimilars were nonexistent prior to the Affordable Care Act of 2010, which created a regulatory regime for the FDA to ...

Express Scripts is joining CVS Health in moving away from offering Humira as a standard prescription drug option for people with arthritis, Crohn's disease and other autoimmune disorders.

Now, Cigna’s Express Scripts is following suit in a move that could further chip away at Humira’s market share. Express Scripts, which is Cigna’s pharmacy benefit unit, is removing branded ...

Beginning in 2025, Express Scripts will favor biosimilars of Humira, including its own private-label version. Beginning in 2025, Express Scripts will remove Humira (adalimumab) from its commercial ...